DVAX - Dynavax Technologies Corporation
| Previous Close | 3.4600 |
| Open | 3.5100 |
| Bid | 3.1100 x 800 |
| Ask | 3.2000 x 1000 |
| Day's Range | 3.1200 - 3.6900 |
| 52 Week Range | 1.8000 - 8.1900 |
| Volume | 1,363,385 |
| Avg. Volume | 1,455,141 |
| Market Cap | 273.218M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1640 |
| Earnings Date | May 05, 2020 - May 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.67 |
- MarketWatch
These 19 companies are working on coronavirus treatments or vaccines — here’s where things stand
A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
- GlobeNewswire
Dynavax Provides Business Update on COVID-19 Pandemic Impact
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today provided a business update in relation to the impact of COVID-19 on the Company’s operations. “During the uncertainty caused by the COVID-19 pandemic, we have acted quickly to focus on four key areas,” commented Ryan Spencer, Chief Executive Officer of Dynavax.
- Thomson Reuters StreetEvents
Edited Transcript of DVAX earnings conference call or presentation 11-Mar-20 8:30pm GMT
Q4 2019 Dynavax Technologies Corp Earnings Call
- MarketWatch
Dynavax's stock rises 10% on expanded CEPI partnership
Shares of Dynavax Technologies Corp. gained 10% in trading on Thursday after the company said it's making its adjuvant technology available to companies developing COVID-19 vaccines through a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), a not-for-profit organization in Oslo that has provided funding to a handful of vaccine developers in this pandemic. Dynavax's adjuvant technology can help provide an increased immune response to a vaccine; the biopharmaceutical company is also working with the University of Queensland, Australia, on vaccine development through a CEPI deal. GlaxoSmithKline , which is lending its adjuvant technology to COVID-19 vaccine development plans, has also partnered with CEPI, the University of Queensland, and Clover Biopharmaceuticals Inc., a Chinese biotechnology company, the same as Dynavax. Dynavax's stock is down 42% year-to-date. The S&P 500 has dropped 23%.
- TipRanks
3 Biotech Stocks to Watch as the Race for a Coronavirus Vaccine Continues
On your mark, get set, go! The race is on to find an effective vaccine against COVID-19, the novel coronavirus that has spread to 471,000 people around the world and claimed more than 21,000 lives. According to the Coalition for Epidemic Preparedness Innovations (CEPI) chief executive Dr. Richard Hatchett, the current pandemic rivals the deadly 1918 Spanish flu, and thus finding a defense against the virus is of utmost importance. “There is a real sense of urgency...because the threat we are facing is unprecedented in the last 100 years in terms of its speed and potential severity,” he commented. As Hatchett estimates that the advancement of a vaccine at the necessary speed will cost $2 billion over the next 12-18 months, it’s no wonder Wall Street is watching the names taking on this formidable foe. Bearing this in mind, we turned to TipRanks’ database to get all the data on three biotech stocks racing to develop a COVID-19 vaccine. The platform showed Wall Street pros believe that among these names, some appear more poised to emerge as a long-term winner. Here’s what we found out. Dynavax Technologies Corporation (DVAX) Using Toll-like Receptor (TLR) biology to modulate the immune system, Dynavax develops innovative vaccines for a number of diseases, with one vaccine against hepatitis B already on the market, Heplisav-B. Since entering the COVID-19 vaccine race, the analyst community has been buzzing about this biotech. DVAX told investors on March 24 that it agreed to a research collaboration with private China-based company, Clover Biopharmaceuticals, to develop an experimental vaccine to prevent COVID-19. As per the terms of the agreement, DVAX will offer the technology used in Heplisav-B, toll-like receptor 9 agonist adjuvant CpG 1018, in order to advance Clover’s vaccine candidate in preclinical studies. Clover’s vaccine is a protein-based coronavirus vaccine (COVID-19 S-Trimer) and uses its proprietary Trimer-Tag technology. If that wasn’t enough, DVAX already stated on March 2 that it will collaborate with the University of Queensland and the CEPI to develop a vaccine candidate for COVID-19. Like its development efforts with Clover, the company will provide its CpG 1018 technology, with a clinical trial set to start in mid-2020. While H.C. Wainwright analyst Edward White doesn’t factor these collaborations into his model, he noted, “...we view them as an upside option on the recent COVID-19 outbreak.” Expounding on his valuation, the five-star analyst added, “We use the net present value of our revenue forecast through 2028, a discount rate of 20%, and a 2x price/sales multiple. Our P/S multiple of 2x is in-line with Dynavax’s peers at approximately 2-5x. We estimate Heplisav-B sales of $57 million in 2020 and $236 million in 2028.” To this end, White maintained both a Buy recommendation and $12 price target. Should the target be met, shares stand to gain 263% in the next twelve months. (To watch White’s track record, click here) What does the rest of the Street think about DVAX’s prospects? It turns out that other pros agree with the H.C. Wainwright analyst. Receiving 100% Street support, this biotech earns a Strong Buy consensus rating. At $16, the average price target comes in above White’s forecast and suggests 356% upside potential. (See Dynavax price targets and analyst ratings on TipRanks)Inovio Pharmaceuticals (INO) Biotech Inovio Pharmaceuticals has already been in the race to develop a vaccine against COVID-19, with it claiming that it had designed its candidate, INO-4800, only three hours after Chinese researchers published the SARS-CoV-2 genetic sequence on January 10. It also received a $5 million grant from the Bill and Melinda Gates Foundation. Now, it’s grabbing headlines for another collaboration, and Wall Street is taking notice. On March 24, Inovio announced that the U.S. Department of Defense (DOD) had given privately-held contract development manufacturing organization (CDMO), Ology Bioservices, an $11.9 million contract to partner with INO on a COVID-19 vaccine candidate. Ology will work with the biotech on DNA technology transfer in order to manufacture INO-4800 as well as quickly deliver the vaccine to the DOD for clinical trials or even emergency use. This development is a significant step forward as INO is gearing up for a Phase 1 trial in the U.S. next month. According to H.C. Wainwright’s Raghuram Selvaraju, “...this partnership would scale up Inovio’s manufacturing capacity and provide sufficient vaccines in a timely fashion to protect the nation’s military personnel against current and future outbreaks.” Selvaraju points out that there are a few advantages of DNA vaccines that could give INO an edge over its peers. Unlike other players in the race, its vaccines can be stored at room temperature for one year or at 37°C for one week, eliminating the need for cold chain logistics. In addition, INO’s injection device is battery-operated and highly portable, making the candidate easy to transport and deploy in any place around the world. The analyst noted, “Accordingly, we believe INO-4800 could be ready for a Phase 2 trial and available for emergency use as of end-2020.” Even though this race features many strong competitors Selvaraju believes, “...the Moderna, BioNTech and Inovio vaccine programs are the furthest along and anticipate that their testing shall be prioritized by regulators and government agencies in order to attempt to effectively combat the crisis.” Taking this into consideration, Selvaraju reiterated a Buy rating and $13 price target. This conveys his confidence in INO’s ability to soar 95% in the next year. (To watch Selvaraju’s track record, click here) Looking at the consensus breakdown, 4 Buys and 2 Holds issued in the last three months coalesce into a Moderate Buy consensus rating. With a $10 average price target, the upside potential lands at 45%. (See Inovio stock analysis on TipRanks) Vir Biotechnology (VIR) With the help of its antibody platform, Vir Biotechnology was able to select a lead clinical vaccine candidate for COVID-19. As a result, it has climbed 62% higher in the last month, attracting significant attention from members of the Street. The company’s lead candidate was designed using an antibody-based approach that binds a conserved epitope on SARS-CoV-2 (COVID-19), which is shared with SARS-CoV-1, the most closely related coronavirus to COVID-19. This could allow it to be effective even as the strains mutate. After it identified the experimental vaccine candidate, VIR transferred it to WuXi Biologics and Biogen in an attempt to expedite development, with a clinical trial slated to begin in 3-5 months. Adding to the good news, Cowen analyst Phil Nadeau points out that “Vir modified the Fc region of the candidate to potentially expand the half-life of the compound and also made a vaccinal modification to allow for the generation of CD8+ memory T cells to the virus to potentially provide long-term immunity.” Explaining the implications of these changes, the analyst wrote, “This modification would allow the therapy to function both as a therapeutic for those infected and also a prophylactic vaccine... Vir envisions that its clinical program will explore use of antibodies (1) In the prevention of disease; (2) The prevention of progression to severe disease; (3) The treatment of severe disease, and (4) the development of vaccines.” As the biotech has successfully identified other antibodies from patients that have recovered from SARS-CoV-2 and SARS-CoV-1 and is using its RNAi platform as well as its innate immunity platform to identify other potential candidates, Nadeau has high hopes for VIR. “We are encouraged that Vir is making rapid progress toward clinical testing of candidates for the treatment of COVID-19... Moreover, as Vir is targeting a region conserved between SARS-CoV-2 and SARS-CoV-1, the candidate could have implications for not only the current pandemic, but may have utility in the future both as a vaccine, and a therapeutic should other coronaviruses emerge,” he commented. Based on all of the above, Nadeau stayed with the bulls. While he reiterated an Outperform rating, he declined to set a specific price target. (To watch Nadeau’s track record, click here) When it comes to the rest of the Street, other analysts take more of a cautious approach. 2 Buys, 1 Hold and 2 Sells add up to a Hold analyst consensus. It should also be noted that the $29.33 average price target implies 5% downside potential. (See Vir Biotechnology stock analysis on TipRanks)
- GlobeNewswire
Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced a collaboration supporting the global effort to develop a vaccine to prevent the coronavirus (COVID-19). Dynavax will make the Company’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018TM, available for the development of effective vaccines against COVID-19. CpG 1018 is the adjuvant used in HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA).
- GlobeNewswire
Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant
Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccineClover advancing.
- Simply Wall St.
Earnings Update: Dynavax Technologies Corporation Just Reported And Analysts Are Trimming Their Forecasts
Shareholders in Dynavax Technologies Corporation (NASDAQ:DVAX) had a terrible week, as shares crashed 37% to US$2.65...
- Zacks
Dynavax Technologies (DVAX) Reports Q4 Loss, Misses Revenue Estimates
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -3.03% and -11.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
Dynavax Technologies: Q4 Earnings Insights
Dynavax Technologies (NASDAQ:DVAX) reported Q4 results.Quarterly Results • Earnings per share were up 31.25% year over year to a loss of $0.44, which missed the estimate by $0.11.• Revenue of $10,570,000 rose by 98.76% year over year, which missed the estimate of $11,960,000.How To Listen To The Conference Call • Webcast URL: http://public.viavid.com/player/index.php?id=138043Technicals • 52-week high: $8.74View more earnings on DVAX• 52-week low was at $2.60• Price action over last quarter: Up 39.45%Company Overview Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.See more from Benzinga * 98 Biotechnology Stocks Moving In Wednesday's Session * 116 Healthcare Stocks Moving In Wednesday's Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results
Full year 2019 HEPLISAV-B® net product revenue of $34.6 million, in line with upwardly-revised guidanceAim to grow 2020 HEPLISAV-B® net product revenue by approximately 70.
- ACCESSWIRE
Dynavax Technologies Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Dynavax Technologies Corp. (NASDAQ:DVAX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 at ...
- Zacks
Dynavax Technologies (DVAX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Dynavax Technologies (DVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is collaborating with the University of Queensland (UQ) as part of a Coalition for Epidemic Preparedness (CEPI) initiative to develop a vaccine to prevent COVID-19. Dynavax is providing technical expertise and the Company’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative. CpG 1018 is the adjuvant used in HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the U.S. Food and Drug Administration (FDA).
- Simply Wall St.
Dynavax Technologies Corporation (NASDAQ:DVAX) Insiders Increased Their Holdings
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- GlobeNewswire
Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11
EMERYVILLE, Calif., Feb. 24, 2020 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will.
- GlobeNewswire
Dynavax to Present at the Cowen 40th Annual Health Care Conference
EMERYVILLE, Calif., Feb. 18, 2020 -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,.
- InvestorPlace
While Risks Remain, VBI Vaccines Stock Is a Buy at Today’s Prices
VBI Vaccines' (NASDAQ:VBIV) stock is on the move. The shares have rallied on the heels of a successful clinical trial. But is it too late to buy the stock?While VBIV has soared around 130% since Nov. 1, more gains could be in the cards. Everything hinges on the company being able to market its Sci-B-Vac hepatitis vaccine in North America and Europe. Source: ravipat/Shutterstock.com VBIV stock is dependent on Sci-B-Vac. There are other drugs in the company's pipeline. But Sci-B-Vac is the only one that's ready for prime time. The company could win big if the vaccine is approved by the key regulators. However, if the company hits additional headwinds, the shares could crash back to their prior lows.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut despite its high risk, VBIV stock may be worth buying at today's prices. The excitement from the results of the Phase 3 trial of Sci-B-Vac has cooled off, sending the shares lower in the past few weeks. This could mean that the shares have reached a solid entry point. Let's see why this high-risk/high-return stock may be a great investment. With Sci-B-Vac's Success More Certain, VBIV Stock Could Head HigherThe success of the company's recent Phase 3 trial bodes well for VBIV stock. But it's important to consider the mixed outcome of the company's prior clinical trial. As InvestorPlace contributor Chris Markoch noted in a recent column, this was Sci-B-Vac's second Phase 3 trial. Back in June, the company completed its initial Phase 3 trial. * 7 Utility Stocks to Buy That Offer Juicy Dividends Based on the outcome of the latter trial, Sci-B-Vac appeared to be more effective than GlaxoSmithKline's (NYSE:GSK) Energix-B. Yet, as Markoch pointed out, " the trial showed that Sci-B-Vac taken in two doses was not as effective as Engerix-B taken in three doses." VBIV stock crashed as investors became less optimistic about Sci-B-Vac's future prospects.But, after this second trial, Sci-B-Vac's viability as a two-dose vaccine is more certain. The second trial's results showed that two doses of Sci-B-Vac were more effective than Energix-B. Thanks to these results, the company plans to seek North American and European approvals in the second half of 2020.What's now key for VBIV stock is how Sci-B-Vac fares against Dynavax's (NASDAQ:DVAX) Heplisav-B. According to a Seeking Alpha contributor, Heplisav-B's key selling point is that it's a two-dose vaccine., while VBIV plans to market its vaccine as a three-dose treatment. But Heplisav-B has had its own headwinds. Rejected twice due to safety concerns by the FDA, Heplisav-B was finally approved in late 2017.Can Sci-B-Vac gain an edge against Heplisav-B? With Heplisav-B already on the market in North America, Dynavax has first-mover advantage over VBIV. But, with VBIV likely to partner with a big pharma company and Dynavax, "going it alone," Sci-B-Vac could wind up having stronger marketing infrastructure behind it.Yet VBIV stock is facing some key risks. Dilution Is Likely, But That's Par for the CourseAs of VBI's last quarterly filing, the company had $53 million of cash. But, given its $54.2 million of operating losses over the previous year, it will need more money going forward, especially since the company is trying to bring Sci-B-Vac to market.Partnering with a big pharma company could minimize its cash burn. However, VBIV appears likely to issue more stock, diluting the value of its shares.But, to monetize Sci-B-Vac, the company needs cash. In the end, a dilutive equity infusion will allow VBIV to fully monetize Sci-B-Vac, ultimately sending the shares higher.As mentioned above, VBIV stock is dependent on a sole catalyst. The success or failure of Sci-B-Vac will drive the future direction of the shares. VBI Vaccines does have other opportunities in its pipeline. These include a chronic hepatitis B infection treatment, as well as a immunotherapy treatment for glioblastoma. But don't expect these drugs to move the needle anytime soon, as both are in the early development stages. The Bottom LineVBIV stock is a high-risk/high-return investment. If Sci-B-Vac is approved by the FDA, the shares could move higher. But, if Sci-B-Vac is not approved, the stock could fall significantly. Yet, with analysts' average price target on the shares standingt at $4.50, VBIV may be worth the risk.After the results of the Phase 3 trial were announced, VBIV stock soared as high as $1.90 per /share. But, after investors' excitement cooled, the shares have slid back to around $1.50. Although the shares are up from their past lows, now may be a great time to buy them.VBIV stock is not a "bet the ranch" situation. But the shares could rally tremendously in the next year. With potential approvals of its vaccine in North America and Europe on the horizon, VBIV could be a big winner in 2020.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Utility Stocks to Buy That Offer Juicy Dividends * 10 Gold and Silver Stocks to Profit Off 2020's Fear Trade * 3 Top Companies That Should Be More Careful With Your Data The post While Risks Remain, VBI Vaccines Stock Is a Buy at Today's Prices appeared first on InvestorPlace.
- Benzinga
The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Amarin ...
- GlobeNewswire
Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer has been appointed Chief Executive Officer and to the Board of Directors. David Novack has been appointed President and Chief Operating Officer, reporting to Mr. Spencer. “Through a rigorous, comprehensive search process, Ryan emerged as the right business leader to guide Dynavax, given his strong command of our business and proven ability to lead and drive commercial execution in a complex operating environment,” commented Arnold L. Oronsky, Ph.D., Chairman of the Board of Directors.
- Insider Monkey
These Hedge Funds Snapped Up Dynavax Technologies Corporation (DVAX) Before Q4 Surge
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- GlobeNewswire
Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Albertsons Companies, one of the largest food and drug retailers in the United States, have partnered to provide HEPLISAV-B at Albertsons Companies’ more than 1,700 pharmacies nationwide, with a special focus on people living with diabetes. Through this partnership, patients will have access to HEPLISAV-B, the only FDA-approved two-dose hepatitis B vaccine for adults that is completed in one month. HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
- Zacks
Is the Options Market Predicting a Spike in Dynavax (DVAX) Stock?
Investors need to pay close attention to Dynavax (DVAX) stock based on the movements in the options market lately.
- GlobeNewswire
Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has filed a report on a cumulative analysis (comprising both required interim analyses) of its post-marketing study of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] for review by the U.S. Food and Drug Administration (FDA). The study is assessing the rates of occurrence of acute myocardial infarction (AMI) in persons receiving HEPLISAV-B compared with Engerix-B. The interim report assesses unadjudicated events of AMI. The event rates in this interim analysis were similar between the two treatment arms.
- Thomson Reuters StreetEvents
Edited Transcript of DVAX earnings conference call or presentation 6-Nov-19 9:30pm GMT
Q3 2019 Dynavax Technologies Corp Earnings Call
